Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
You may also be interested in...
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.